Literature DB >> 6805535

A variant of von Willebrand's disease with abnormal expression of factor VIII procoagulant activity.

R R Montgomery, W E Hathaway, J Johnson, L Jacobson, W Muntean.   

Abstract

Reports on variants of von Willebrand's disease are numerous, but many of these are based on tests that will show marked fluctuations with time and tests that might not be similar in affected family members. This report describes 8 patients with a new variant of von Willebrand';s disease in which there is a normal APTT, slightly reduced one-stage factor VIII:C assay (VIII:C-1), and a drastically reduced two-stage factor VIII:C assay (VIII:C-2). The VIII:C in this variant is more readily adsorbed to AI(OH)3. This variability in VIII:C assays and excessive adsorption to AI(OH)3 are corrected by the addition of either hemophilic plasma or hemophilic factor-VIII-related antigen. This variant is stable with restudy on multiple occasions and is inherited in a stable fashion in three generations of one family. The multimeric structure of the VIIIR:Ag appears normal, although the concentration is moderately reduced. The differences in functional activity, the adsorption to AI(OH)3, and the differences between functional and antigenic (VIII:C Ag) assays of VIII:C support that this is a functional abnormality of type I von Willebrand's disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6805535

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.

Authors:  Daniel B Bellissimo; Pamela A Christopherson; Veronica H Flood; Joan Cox Gill; Kenneth D Friedman; Sandra L Haberichter; Amy D Shapiro; Thomas C Abshire; Cindy Leissinger; W Keith Hoots; Jeanne M Lusher; Margaret V Ragni; Robert R Montgomery
Journal:  Blood       Date:  2011-12-23       Impact factor: 22.113

2.  Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.

Authors:  V H Flood; J C Gill; P A Christopherson; J S Wren; K D Friedman; S L Haberichter; R G Hoffmann; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

3.  Rapid discrimination of the phenotypic variants of von Willebrand disease.

Authors:  Jonathan C Roberts; Patti A Morateck; Pamela A Christopherson; Ke Yan; Raymond G Hoffmann; Joan Cox Gill; Robert R Montgomery
Journal:  Blood       Date:  2016-02-25       Impact factor: 22.113

Review 4.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

5.  Defective collagen binding and increased bleeding in a murine model of von Willebrand disease affecting collagen IV binding.

Authors:  T L Slobodianuk; C Kochelek; J Foeckler; S Kalloway; H Weiler; V H Flood
Journal:  J Thromb Haemost       Date:  2018-12-18       Impact factor: 5.824

Review 6.  Platelet and endothelial expression of clotting factors for the treatment of hemophilia.

Authors:  Robert R Montgomery; Qizhen Shi
Journal:  Thromb Res       Date:  2012-03-14       Impact factor: 3.944

7.  A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.

Authors:  W F Bahou; D Ginsburg; R Sikkink; R Litwiller; D N Fass
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

Review 8.  Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A.

Authors:  Steven W Pipe; Robert R Montgomery; Kathleen P Pratt; Peter J Lenting; David Lillicrap
Journal:  Blood       Date:  2016-09-01       Impact factor: 22.113

9.  Diagnosis of Bernard-Soulier syndrome and Glanzmann's thrombasthenia with a monoclonal assay on whole blood.

Authors:  R R Montgomery; T J Kunicki; C Taves; D Pidard; M Corcoran
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

10.  Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function.

Authors:  V H Flood; K D Friedman; J C Gill; P A Morateck; J S Wren; J P Scott; R R Montgomery
Journal:  J Thromb Haemost       Date:  2009-08-19       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.